Your browser doesn't support javascript.
loading
Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets.
Reva, Boris A; Omelchenko, Tatiana; Nair, Sujit S; Tewari, Ashutosh K.
Afiliação
  • Reva BA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: boris.reva@mssm.edu.
  • Omelchenko T; Cell Biology Program, Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Nair SS; The Department of Urology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1272, New York, NY 10029, USA.
  • Tewari AK; The Department of Urology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1272, New York, NY 10029, USA.
Urol Clin North Am ; 47(4S): e9-e16, 2020 Nov.
Article em En | MEDLINE | ID: mdl-33446324
Complex immune evasion mechanisms and lack of biomarkers predicting responsiveness to immune checkpoint blockade therapies compromise immunotherapy's therapeutic efficacy for patients with prostate cancer. The authors review established and nominated immune evasion mechanisms in prostate cancer and discuss how the precise treatment strategies can be developed to improve efficacy of immunotherapy.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Interferon gama / Evasão Tumoral / Inibidores de Checkpoint Imunológico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Interferon gama / Evasão Tumoral / Inibidores de Checkpoint Imunológico Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article